TP53 and diffuse large B-cell lymphoma: For example, ATR inhibition by ceralasertib as a single agent and in combination with either CHK1 or WEE1 inhibitors was effective in several preclinical models of Mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) regardless of their TP53, MYC, and ATM mutational status in vitro and in vivo studies [137].